Cardiovascular implications of proteinuria: an indicator of chronic kidney disease (Q37437174)

20 August 2017

1 reference

title

Cardiovascular implications of proteinuria: an indicator of chronic kidney disease (English)

1 reference

20 August 2017

1 reference

Varun Agrawal

1

1 reference

20 August 2017

Victor Marinescu

series ordinal

2

1 reference

20 August 2017

Mohit Agarwal

series ordinal

3

1 reference

20 August 2017

Peter A McCullough

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

Nature Reviews Cardiology

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

301-311

1 reference

20 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrcardio.2009.11

20 August 2017

0 references

cites work

Leptin and renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Atherosclerosis and the two faces of endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Testing for chronic kidney disease: a position statement from the National Kidney Foundation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Microalbuminuria and cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Screening for proteinuria in US adults: a cost-effectiveness analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Chronic kidney disease and mortality risk: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

The increased risk of coronary heart disease associated with nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Incidence and risk factors for stroke in American Indians: the Strong Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Proteinuria and interstitial injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

How does proteinuria cause progressive renal damage?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Chronic renal failure: a cardiovascular risk factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Prevalence of hypertension in renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Proteinuria as a significant determinant of hypertension in a normotensive screened cohort in Okinawa, Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Correlates of systolic hypertension in patients with chronic kidney disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Telmisartan, ramipril, or both in patients at high risk for vascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Coronary artery calcification scores in patients with chronic kidney disease prior to dialysis: reliability as a trial outcome measure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Familial aggregation of coronary artery calcium in families with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Determinants of coronary artery calcification in diabetics with and without nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Hyperlipidemia in patients with chronic renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effect of pravastatin on proteinuria in patients with well-controlled hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Statin induced proteinuria: renal injury or renoprotection?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Evidence of transcellular permeability pathway in microvessels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Role of oxidative modifications in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Endothelial dysfunction and inflammation in asymptomatic proteinuria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Glomerular disease related to anti-VEGF therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Gross proteinuria is a strong risk predictor for cardiovascular mortality in Brazilian type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

The prognostic significance of proteinuria: the Framingham study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Rising tide of cardiovascular disease in American Indians. The Strong Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Albuminuria and incident coronary heart disease in Australian Aboriginal people

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population--the Ohasama study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Beneficial impact of spironolactone in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Aliskiren combined with losartan in type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.11

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

31 March 2020

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

12 December 2020

Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines

1 reference

12 December 2020

Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis

1 reference

12 December 2020

Hemorheology, plasma protein composition and von Willebrand factor in type I diabetic nephropathy

1 reference

12 December 2020

Proteinuria: how to evaluate an important finding

1 reference

12 December 2020

Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study

1 reference

12 December 2020

Transport of macromolecules through microvascular walls

1 reference

12 December 2020

Glomerular and hormonal responses to dietary protein intake in human renal disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2009.11

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference